This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In this CRA Insights, we assess the actions and impact of the second Trump Administration during the first 100 days that directly affect healthcare policy, drug development, and payment models.
This Insight collates the 15 healthcare-related executive orders issued by President Trump, outlining what healthcare stakeholders need to know and what policy areas to watch as further developments unfold.
CRA consultant Becky Davis was interviewed at Asembia AXS25 Summit to highlight her presentation titled “GLP-1s: Riding the Wave of Innovative Medications.”
CRA consultant Becky Davis was interviewed by Managed Healthcare Executive at Asembia AXS25 Conference.
CRA is a proud sponsor of the conference that aims to increase the prominence of women through professional development, substantive legal discussion, and...
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
